Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Emerald Mutual Fund Advisers Trust

Emerald Mutual Fund Advisers Trust grew its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 92.0% during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 243,795 shares of the biopharmaceutical company’s stock after purchasing an additional 116,832 shares during the quarter. Emerald Mutual Fund Advisers Trust’s holdings in Celldex Therapeutics were worth $8,287,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its holdings in Celldex Therapeutics by 16.3% in the fourth quarter. Vanguard Group Inc. now owns 3,046,331 shares of the biopharmaceutical company’s stock valued at $120,817,000 after buying an additional 427,827 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Celldex Therapeutics by 10.0% in the first quarter. Principal Financial Group Inc. now owns 13,153 shares of the biopharmaceutical company’s stock worth $552,000 after purchasing an additional 1,194 shares during the period. Capstone Investment Advisors LLC boosted its holdings in Celldex Therapeutics by 50.7% in the first quarter. Capstone Investment Advisors LLC now owns 19,065 shares of the biopharmaceutical company’s stock worth $800,000 after purchasing an additional 6,412 shares during the period. Jennison Associates LLC increased its stake in Celldex Therapeutics by 3,327.0% during the first quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock valued at $28,879,000 after purchasing an additional 668,002 shares during the last quarter. Finally, Swiss National Bank raised its holdings in shares of Celldex Therapeutics by 17.8% during the first quarter. Swiss National Bank now owns 114,300 shares of the biopharmaceutical company’s stock worth $4,797,000 after purchasing an additional 17,300 shares during the period.

Analyst Ratings Changes

CLDX has been the subject of a number of recent research reports. Wells Fargo & Company raised shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 26th. The Goldman Sachs Group began coverage on Celldex Therapeutics in a report on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company. Citigroup initiated coverage on Celldex Therapeutics in a report on Monday, October 7th. They issued a “buy” rating and a $70.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Monday, October 28th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research note on Monday, September 16th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $62.25.

Celldex Therapeutics Stock Performance

NASDAQ:CLDX opened at $25.68 on Friday. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of -9.37 and a beta of 1.60. Celldex Therapeutics, Inc. has a 1 year low of $23.72 and a 1 year high of $53.18. The business has a fifty day moving average of $34.89 and a 200-day moving average of $36.23.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.05. Celldex Therapeutics had a negative net margin of 1,809.18% and a negative return on equity of 23.66%. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $1.13 million. On average, equities research analysts predict that Celldex Therapeutics, Inc. will post -2.5 EPS for the current year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.